Tikvah Therapeutics to Present At Lazard Capital Markets Healthcare Conference On November 27
November 16, 2007 07:59 ET
|
Tikvah Therapeutics, Inc.
ATLANTA, Nov. 16, 2007 (PRIME NEWSWIRE) -- Tikvah Therapeutics, Inc., an Atlanta, GA-based biopharmaceutical company focused on new treatment options to better manage central nervous system diseases,...
Tikvah Therapeutics Selected for 'Main-Stage' Presentation At the Ninth Annual Southeastern BIO Investor Forum
November 01, 2007 07:59 ET
|
Tikvah Therapeutics, Inc.
ATLANTA, Nov. 1, 2007 (PRIME NEWSWIRE) -- Tikvah Therapeutics, Inc., an Atlanta, GA-based biopharmaceutical company focused on new treatment options to better manage central nervous system diseases,...
Tikvah Therapeutics, Inc. and Chakra Biotech Pte. Ltd. Establish Collaboration to Accelerate the Development of Novel Antipsychotic Compounds
September 05, 2007 08:00 ET
|
Tikvah Therapeutics, Inc.
ATLANTA and SINGAPORE, Sept. 5, 2007 (PRIME NEWSWIRE) -- Tikvah Therapeutics, Inc., a biopharmaceutical company focused on new treatment options to better manage central nervous system diseases, and...
Tikvah Therapeutics Signs Agreement to Develop and Commercialize LY156735, a Second Generation Melatonin Agonist, for Circadian Rhythm and Sleep Disorders
August 29, 2007 08:00 ET
|
Tikvah Therapeutics, Inc.
ATLANTA, Aug. 29, 2007 (PRIME NEWSWIRE) -- Atlanta-based Tikvah Therapeutics, Inc., a biopharmaceutical company focused on new treatment options to better manage central nervous system diseases,...
Families of SMA and Tikvah Therapeutics, Inc. Establish Collaboration to Test Potential Treatment for Spinal Muscular Atrophy
August 28, 2007 13:00 ET
|
Tikvah Therapeutics, Inc.
LIBERTYVILLE, Ill. and ATLANTA, Aug. 28, 2007 (PRIME NEWSWIRE) -- Families of Spinal Muscular Atrophy (FSMA) and Tikvah Therapeutics, Inc. today announced that they have established a collaboration to...
Dr. Garratt W. Ponder Named Vice President of Pharmaceutical Development for Atlanta-Based Tikvah Therapeutics, Inc.
August 22, 2007 08:00 ET
|
Tikvah Therapeutics, Inc.
ATLANTA, Aug. 22, 2007 (PRIME NEWSWIRE) -- Tikvah Therapeutics, Inc. has appointed Dr. Garratt W. Ponder Vice President of Pharmaceutical Development.
Dr. Ponder joins Tikvah Therapeutics with over...
FDA Grants Tikvah Therapeutics, Inc. Orphan Drug Status for Sodium Phenylbutyrate for the Treatment of Spinal Muscular Atrophy
August 20, 2007 08:00 ET
|
Tikvah Therapeutics, Inc.
ATLANTA, Aug. 20, 2007 (PRIME NEWSWIRE) -- Tikvah Therapeutics, Inc., a biopharmaceutical company focused on new treatment options to better manage central nervous system diseases, announced today...
Tikvah Therapeutics Names Jack W. Callicutt Vice President and Chief Financial Officer
August 09, 2007 08:00 ET
|
Tikvah Therapeutics, Inc.
ATLANTA, Aug. 9, 2007 (PRIME NEWSWIRE) -- Tikvah Therapeutics, Inc., a biopharmaceutical company focused on new treatment options to better manage central nervous system diseases, announced today the...
Tikvah Therapeutics Licenses Unique Solution Formulations Useful in the Treatment of Neurodegenerative Diseases, Including Spinal Muscular Atrophy, From Navinta, LLC
August 07, 2007 08:00 ET
|
Tikvah Therapeutics, Inc.
ATLANTA, Aug. 7, 2007 (PRIME NEWSWIRE) -- Tikvah Therapeutics, Inc. (Tikvah), a biopharmaceutical company focused on new treatment options to better manage central nervous system diseases, and Ewing,...
Tikvah Therapeutics Names Nathan Andrew Shapira, M.D., Ph.D. Executive Director of Clinical Research and Development and Deputy Chief Medical Officer
August 02, 2007 08:00 ET
|
Tikvah Therapeutics, Inc.
ATLANTA, Aug. 2, 2007 (PRIME NEWSWIRE) -- Tikvah Therapeutics, Inc., a biopharmaceutical company focused on new treatment options to better manage central nervous system diseases, announced today the...